Science1 publisherNot yet confirmed elsewhere2 min readPublished
Asymmetric synthesis wins the 2026 chemistry Nobel for making one mirror-image form of a molecule
Two researchers won the 2026 chemistry Nobel for asymmetric synthesis, a way to make only one mirror-image form of a molecule. One lab using it says mixed Alzheimer's trial results for resveratrol may trace to two forms of the compound.
The Scientist · Science desk

What happened
- Thalidomide, the morning sickness drug behind thousands of birth defects and miscarriages, has one sedative form and one thought to disrupt development.
- Tyrosine is an exception among amino acids because the enzyme TyrRS activates both its L and D forms for protein synthesis.
- In rat brain cells in a dish, rising L-tyrosine lowered TyrRS levels, while D-tyrosine lowered TyrRS and also killed the neurons.
- The same lab reports that Alzheimer's patients whose brains show raised tyrosine also have depleted TyrRS.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- capability Making one mirror form at a time lets a lab dose each form separately, the step the author's team says exposed a possible split between a helpful and a toxic resveratrol form.
- constraint Producing only the safe form does not protect patients when the two forms swap inside the body, as thalidomide's do, so the benefit holds only for drugs whose forms stay fixed.
- decision If the two-forms account is right, resveratrol trials that did not record which form they dosed cannot be compared, and future protocols would have to specify it.
Chiral molecules have the same atoms and the same bonds, arranged as two mirror images that cannot be laid one on top of the other, like a pair of hands [3]. That arrangement can change a molecule's effect in the body drastically. A target shaped for a right-handed molecule will not take the left-handed one [3]. Asymmetric synthesis lets a drug chemist make the hand they want, and only that one [1][2].
Resveratrol is the newer and thinner part of this story. The compound, found in red grapes and peanuts, has given inconsistent results in clinical trials for Alzheimer's disease [11][9]. Writing in The Conversation, a researcher whose lab used the prize-winning reactions says the inconsistency may come from two different forms of the compound being used: one that may help cognition and memory, and one that may be toxic to the nervous system [10]. Those hedges are honest. The account does not say which trials used which form, at what dose, or in what proportion. I'd want to see that table before treating the trials as explained. If past results split cleanly by the form each trial dosed, the case gets strong. If every trial dosed a mixture, the idea explains little.
Most of the laboratory detail in the piece concerns tyrosine, an amino acid that the enzyme TyrRS will activate in either mirror form [6]. The design has two steps. Rat brain cells in a dish received rising amounts of each form, and the team tracked the enzyme and whether the cells survived [7]. Then the lab looked at the brains of Alzheimer's patients with raised tyrosine [12].
Only the dish supports a causal reading, because the researchers set the dose. In patients, high tyrosine and low enzyme were found together. An association in tissue cannot say whether one drives the other or whether the disease drives both. The researcher frames that step as a hypothesis. "Our hypothesis is that as tyrosine levels in the brain increase, TyrRS enzyme levels drop and cause damaging effects on the brains of those with Alzheimer's," the researcher wrote [13].
There is separate reason to take tyrosine toxicity seriously. When the enzymes that consume tyrosine are missing, the build-up can damage the nervous system [8]. The thing this doesn't tell you is whether D-tyrosine, the form that killed neurons in the dish, reaches anything like the dish amounts in a human brain [7].
What to watch
- Publication of data matching each past resveratrol Alzheimer's trial to the form and dose it used.
- Whether the D-tyrosine neuron-killing result holds in living animals, beyond rat cells in a dish.
- Measurements of D-tyrosine levels in Alzheimer's patients' brains compared with the amounts given to the cultured cells.